In clinical therapy for muscle wasting in cachexia patients, myostatin inhibitors have been widely investigated for therapeutic treatments (Gallot et al., 2014; Zhou et al., 2010); thus, the myostatin inhibitor SRP4623P was also used as a positive control to prevent muscle wasting (Smith and Lin, 2013). This evidence concerns the gene MSTN and Cachexia.